Johnson & Johnson on Thursday said it will record a nearly $700 million impairment charge in the first quarter of 2019 related to the abandoned development of its experimental antiviral drug, AL-8176.
from Reuters: Health https://ift.tt/2Fs2nb1
via
IFTTT
0 comments: